![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Introduction
Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13.
Areas covered
We systematically searched the literature which published on peer-reviewed journals from January 2010 to June 2022. The literature search was conducted in the following electronic databases: PubMed, Web of Science, Embase, the Cochrane Library, CNKI, Wanfang database, VIP database. We identified 1827 records from the database search. After excluding 511 duplicates, 1314 records were screened, of which 156 records were retained for the full-text reviews. A total of 44 studies were included in the review. Among the included studies, 33 studies were economic evaluations of PCV13 among children, and 11 studies were conducted among adults. The literature search initiated in April, 2022, and updated in June 2022.
Expert opinion
Vaccination with PCV13 was found to significantly reduce the mortality and morbidity of pneumococcal diseases and was cost-effective compared to no vaccine or several other pneumococcal vaccines (e.g. PCV10, PPV23). Future research is advised to expand economic evaluations of PCV13 combined with dynamic model to enhance methodologic rigor and prediction accuracy.
Article highlights
Pneumococcal diseases (PDs) have become a serious public health problem around the world and the Streptococcus Pneumoniae (SPn) or pneumococcus is acknowledged as the main cause of PDs.
Pneumococcal vaccination is the most cost-effective measure to prevent SPn infection. However, the evidence-based cost-effectiveness of PCV13 is unclear.
The current body of situation is limited largely to a few systematic reviews of the cost-effectiveness of PCVs in children or adults separately in some regions, with no systematic reviews have summarized the cost-effectiveness results of PCV13 among populations of both children and adults in all countries.
We conducted a comprehensive literature research for economic evaluation studies on PCV13 both children and adults populations. This systematic review suggests that the PCV13 vaccine may be cost-effective in children and adults.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or mending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contributions
CPW, ZWW and XYW conceived the study, performed the study selection, data extraction and analysis, and revised the draft manuscript. YZD, HWS, YFX, MY and JWC performed the literature search, study selection, data extraction and analysis. YZD and JJL wrote the original draft manuscript. XYW, YW, YYW and TZ reviewed and revised the draft manuscript. All authors wrote the manuscript, read and approved the submitted version.